29800-43-9

Usage

Uses

Used in Fragrance and Flavor Industry:
Oxo-(2-oxo-cycloheptyl)-acetic acid ethyl ester is used as a fragrance ingredient in consumer products for its pleasant odor. It contributes to the creation of various scents in perfumes, colognes, and other fragranced products.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, Oxo-(2-oxo-cycloheptyl)-acetic acid ethyl ester serves as a key component in the synthesis of various organic compounds. Its unique properties make it valuable in the development of new drugs and medicinal formulations.
Used in Chemical Synthesis:
Oxo-(2-oxo-cycloheptyl)-acetic acid ethyl ester is utilized as a starting material or intermediate in the synthesis of other organic compounds. Its reactivity and functional groups make it a versatile building block for creating a wide range of chemical products.
Safety Precautions:
It is crucial to handle Oxo-(2-oxo-cycloheptyl)-acetic acid ethyl ester with care, as it can pose hazards if not used properly. Proper safety measures, including the use of personal protective equipment and adherence to handling guidelines, should be followed to minimize risks associated with this chemical compound.

Upstream product

• 95-92-1 oxalic acid diethyl ester 
• 502-42-1 cycloheptanone 

Downstream Products

• 144148-41-4 Ethyl 2,4,5,6,7,8-hexahydrocycloheptapyrazole-3-carboxylate 
• 98310-09-9 ethyl 1-phenyl-1,4,5,6,7,8-hexahydrocyclohepta[c]pyrazole-3-carboxylate 
• 97393-57-2 1-phenyl-1,4,5,6,7,8-hexahydrocyclohepta[c]pyrazole-3-carboxylic acid 

Relevant academic research and scientific papers

A new synthesis of highly functionalized 2H-pyran derivatives

Ethyl oxo-(2-oxo-cycloalkyl)-ethanoates undergo a smooth reaction with triphenylphosphine and dialkyl acetylenedicarboxylates via intramolecular Wittig reaction to produce spiro-cyclobutene derivatives. These spiro systems undergo electrocyclic ring opening reaction to produce electron-deficient 1,3-dienes, which spontaneously cyclize to 2H-pyran derivatives.

Design, Synthesis, and Biological Activity of Novel Heptacyclic Pyrazolamide Derivatives: A New Candidate of Dual-Target Insect Growth Regulators

Insect growth regulators (IGRs) can cause abnormal growth and development in insects, resulting in incomplete metamorphosis or even death of the larvae. Ecdysone receptor (EcR) and chitinase in insects play indispensable roles in the molting process. Ecdysone analogues and chitinase inhibitors are considered as potential IGRs. In order to find new and highly effective IGR candidates, based on the structure-activity relationship and molecular docking results of the active compound 6i (3-(tert-butyl)-N-(4-(tert-butyl)phenyl)-1-phenyl-1H-pyrazole-5-carboxamide) discovered in our previous work, we changed the t-butyl group on the pyrazole ring into heptacycle to enhance the hydrophobicity. Consequently, a series of novel heptacyclic pyrazolamide derivatives were designed and synthesized. The bioassay results demonstrated that some compounds showed obvious insecticidal activity. Especially, D-27 (N-(4-(tert-butyl)phenyl)-2-phenyl-2,4,5,6,7,8-hexahydrocyclohepta[c]pyrazole-5-carboxamide) showed good activities against Plutella xylostella (LC50, 51.50 mg·L-1) and Mythimna separata (100percent mortality at 2.5 mg·L-1). Furthermore, protein validation indicated that D-27 acts not only on the EcR but also on chitinase Of ChtI. Molecular docking and molecular dynamics simulation explained the vital factors in the interaction between D-27 and receptors. D-27 may be a new lead candidate with a dual target in which Of ChtI shall be the main one. This work created a new starting point for discovering a novel type of IGRs.

New lead discovery of insect growth regulators based on the scaffold hopping strategy

Insect growth regulators (IGRs), which can interrupt or inhibit pest life cycles, are low-toxicity pesticides widely used in integrated pest management (IPM). Ecdysone analogues and chitinase inhibitors are familiar IGRs that have attracted considerable attention because of their unique modes of action and low toxicity to non-target organisms. To find new and highly effective candidate IGRs with novel mechanisms, D-08 (N-(4-(tert-butyl)phenyl)-2-phenyl-2,4,5,6,7,8-hexahydrocyclohepta[c]pyrazole-5-carboxamide) was chosen as a lead compound, and a series of novel heptacyclic pyrazolamide derivatives were designed and synthesized using the scaffold hopping strategy. The bioassay showed that III-27 (N-(2-methylphenethyl)-1-phenyl-1,4,5,6,7,8-hexahydrocyclohepta[c]pyrazole-5-carboxamide) had excellent activity against Plutella xylostella. Protein verification and molecular docking indicated that III-27 could act on both the ecdysone receptor (EcR) and Ostrinia furnacalis chitinase (Of ChtI) and is a promising new lead IGRs. The interaction mechanism of III-27 with EcR and Of ChtI was then studied by molecular docking. These results provide important guidance for the study of new dual-target IGRs.

Pyrazolo-cyclo-3-carboxamide analog and its preparation method and use

The invention provides a pyrazolo-cyclo-3-carboxamide analog. The pyrazolo-cyclo-3-carboxamide analog has a structure shown in the general formula I. In the formula I, n is an integer of 1-3, R1 represents C1-C10 alkyl, cyclopropyl, cyclohexyl or phenyl, hydrogen in the phenyl can be replaced by one or more of halogens, a cyano group, C1-C10 alkyl and C1-C10 alkoxy group. The pyrazolo-cyclo-3-carboxamide analog is designed according to active conformation of a bishydrazide compound, has obvious effects of killing agricultural pests and can be used as a pesticide in agriculture.

Synthesis, Structure-Activity Relationship, and Pharmacophore Modeling Studies of Pyrazole-3-Carbohydrazone Derivatives as Dipeptidyl Peptidase IV Inhibitors

Type 2 diabetes mellitus (T2DM) is a metabolic disease and a major challenge to healthcare systems around the world. Dipeptidyl peptidase IV (DPP-4), a serine protease, has been rapidly emerging as an effective therapeutic target for the treatment for T2DM. In this study, a series of novel DPP-4 inhibitors, featuring the pyrazole-3-carbohydrazone scaffold, have been discovered using an integrated approach of structure-based virtual screening, chemical synthesis, and bioassay. Virtual screening of SPECS Database, followed by enzymatic activity assay, resulted in five micromolar or low-to-mid-micromolar inhibitory level compounds (1-5) with different scaffold. Compound 1 was selected for the further structure modifications in considering inhibitory activity, structural variability, and synthetic accessibility. Seventeen new compounds were synthesized and tested with biological assays. Nine compounds (6e, 6g, 6k-l, and 7a-e) were found to show inhibitory effects against DPP-4. Molecular docking models give rational explanation about structure-activity relationships. Based on eight DPP-4 inhibitors (1-5, 6e, 6k, and 7d), the best pharmacophore model hypo1 was obtained, consisting of one hydrogen bond donor (HBD), one hydrogen bond acceptor (HBA), and two hydrophobic (HY) features. Both docking models and pharmacophore mapping results are in agreement with pharmacological results. The present studies give some guiding information for further structural optimization and are helpful for future DPP-4 inhibitors design.

Discovery of small molecules that inhibit melanogenesis via regulation of tyrosinase expression

5,6,7,8-Tetrahydro-4H-cyclohepta[d]isoxazole derivatives were synthesized and evaluated as a novel class of inhibitors for α-melanocyte-stimulating hormone (α-MSH) induced melanogenesis in a mouse melanoma B16F10 cell line. Compound 8e (IC50 = 0.67 μM), 8h (IC50 = 1.01 μM) and 9b (IC50 = 0.99 μM) exhibited a potent inhibitory activity approximately 85- to 126-fold greater than kojic acid, a well-known potent inhibitor. A biochemical study indicates that the activity of this series should be displayed via down-regulation of the expression of tyrosinase.

Pyrrole and pyrazole DAAO inhibitors

Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein R1 and R2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR5; or R1 and R2, taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR6R7)n; R3 is hydrogen, alkyl or M+; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof; Z is N or CR4; R4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR5; R5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R6 and R7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R1, R2 and R4 is other than hydrogen; and at least one of X and Y is (CR6R7)n. D-serine or cycloserine may be coadministered along with the compound of formula I.